- Home
- MNPR vs ANGO Comparison
MNPR vs ANGO Comparison
Compare MNPR & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- ANGO
- Stock Information
- Founded
- MNPR 2014
- ANGO 1988
- Country
- MNPR United States
- ANGO United States
- Employees
- MNPR N/A
- ANGO N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- ANGO Medical/Dental Instruments
- Sector
- MNPR Health Care
- ANGO Health Care
- Exchange
- MNPR Nasdaq
- ANGO Nasdaq
- Market Cap
- MNPR 250.0M
- ANGO 279.1M
- IPO Year
- MNPR 2019
- ANGO 2004
- Fundamental
- Price
- MNPR $40.25
- ANGO $10.33
- Analyst Decision
- MNPR Strong Buy
- ANGO Strong Buy
- Analyst Count
- MNPR 4
- ANGO 3
- Target Price
- MNPR $43.00
- ANGO $13.00
- AVG Volume (30 Days)
- MNPR 71.2K
- ANGO 606.8K
- Earning Date
- MNPR 03-27-2025
- ANGO 04-03-2025
- Dividend Yield
- MNPR N/A
- ANGO N/A
- EPS Growth
- MNPR N/A
- ANGO N/A
- EPS
- MNPR N/A
- ANGO N/A
- Revenue
- MNPR N/A
- ANGO $286,498,000.00
- Revenue This Year
- MNPR N/A
- ANGO N/A
- Revenue Next Year
- MNPR N/A
- ANGO $6.63
- P/E Ratio
- MNPR N/A
- ANGO N/A
- Revenue Growth
- MNPR N/A
- ANGO N/A
- 52 Week Low
- MNPR $1.72
- ANGO $5.26
- 52 Week High
- MNPR $54.30
- ANGO $13.50
- Technical
- Relative Strength Index (RSI)
- MNPR 49.34
- ANGO 42.75
- Support Level
- MNPR $38.80
- ANGO $10.13
- Resistance Level
- MNPR $45.60
- ANGO $11.07
- Average True Range (ATR)
- MNPR 5.19
- ANGO 0.40
- MACD
- MNPR -1.50
- ANGO -0.16
- Stochastic Oscillator
- MNPR 9.37
- ANGO 14.18
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.